Berman, J; Bryceson, ADM; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA; (2006) Miltefosine: issues to be addressed in the future. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100 Su. S41-4. ISSN 0035-9203 DOI: https://doi.org/10.1016/j.trstmh.2006.02.009 Full text not available from this repository.

Bhattacharya, SK; Jha, TK; Sundar, S; Thakur, CP; Engel, J; Sindermann, H; Junge, K; Karbwang, J; Bryceson, ADM; Berman, JD; (2004) Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clinical infectious diseases, 38 (2). pp. 217-221. ISSN 1058-4838 DOI: https://doi.org/10.1086/380638 Full text not available from this repository.

Croft, SL; Seifert, K; Yardley, V; (2006) Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 123 (3). pp. 399-410. ISSN 0971-5916 https://researchonline.lshtm.ac.uk/id/eprint/11722

Luna, KP; Hernandez, IP; Rueda, CM; Zorro, MM; Croft, SL; Escobar, P; (2009) In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica, 29 (3). pp. 448-455. ISSN 0120-4157 https://researchonline.lshtm.ac.uk/id/eprint/4496 Full text not available from this repository.

Perez-Victoria, FJ; Sanchez-Canete, MP; Seifert, K; Croft, SL; Sundar, S; Castanys, S; Gamarro, F; (2006) Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug resistance updates, 9 (1-2). pp. 26-39. ISSN 1368-7646 DOI: https://doi.org/10.1016/j.drup.2006.04.001 Full text not available from this repository.